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Abstract
Background: To evaluate activity and tolerability of two anthracycline-containing regimens as first-line treatment
for anthracycline-naïve relapsed breast cancer patients.
Methods: Patients with relapsed breast cancer not previously treated with adjuvant anthracyclines were randomly
assigned to epirubicin/vinorelbine (arm A: EPI/VNB, EPI 90 mg/m
2 on day 1, VNB 25 mg/m
2 on days 1,5 plus G-CSF
subcutaneously on days 7-12, with cycles repeated every 21 days), or to pegylated liposomal doxorubicin/VNB (arm
B: PLD/VNB, PLD 40 mg/m
2 on day 1, VNB 30 mg/m
2 on days 1, 15, with cycles repeated every 4 weeks). Primary
objective was to evaluate the efficacy of the two regimens in terms of response rate, secondarily toxicity,
progression free survival and overall survival.
Results: One hundred and four patients have been enrolled (arm A 54, arm B 50): characteristics were well
balanced between the 2 arms. Responses were as follows: arm A, 3 (5.6%) CR, 20 (37%) PR, (ORR 42.6%, 95%CI
29.3%-55.9%); arm B, 8 (16%) CR, 18 (36%) PR, (ORR 52%, 95%CI 38.2%-65.8%). Median progression free survival was
10.7 months in arm A (95% CI, 8.7-12.6), and 8.8 months in arm B (95% CI, 7.1-10.5). Median overall survival was
34.6 months in arm A (95%CI, 19.5-49.8) and 24.8 months in arm B (95%CI, 15.7-33.9). As toxicity concerns, both
treatment regimens were well tolerated; myelosuppression was the dose-limiting toxicity, with G3-4 neutropenia
occurring in 18.5% and 22% of the patients of arm A and B, respectively. No relevant differences in main toxic
effects have been observed between the two arms, except for alopecia, more common in arm A, and cutaneous
toxicity, observed only in arm B. No clinical congestive heart failures have been observed, one case of
tachyarrhythmia was reported after the last EPI/VNB cycle, and two reversible ≥ 20% LVEF decreases have been
observed in arm A.
Conclusions: Both anthracycline- containing regimens evaluated in the present study seem to be active and with
a satisfactory tolerability in anthracycline-naïve relapsed breast cancer patients.
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Anthracyclines are among the most active drugs in
advanced breast cancer, with response rates as single
agents of approximately 30% to 50%, and anthracycline-
based regimens have been shown to determine significant
advantages in response rate and progression free survival
over non- anthracycline-containing regimens [1,2]. The
potential benefit of conventional anthracyclines, mainly
doxorubicin, is limited by the risk of cardiac dysfunction,
clearly related to cumulative dose, and as a result
it might be necessary to withdraw treatment or to avoid
re-treatment even in potential responders patients.
To minimize toxic effects, doxorubicin has often been
replaced by epirubicin (EPI) ,k n o w nt ob ea sa c t i v ea s
the parent compound and with lower toxicity, particu-
larly cardiac toxicity [3-6]. As dose-response concerns,
higher EPI doses, both as single agent and in combina-
tion regimens, seem to be more efficacious than lower
doses [7-10].
Vinorelbine (VNB) has established activity as single-
agent in breast cancer, both as first-line and salvage treat-
ment [11,12], and its good tolerance profile makes it an
excellent candidate for combination regimens, so it was a
logical step to combine VNB with anthracyclines, and the
combination with doxorubicin yielded a 74% of response
rate, a median duration of response of 12 months and a
median survival of 27.5 months as first-line treatment
[13]. Other trials employing this combinations confirmed
positive results [14-16]. Preliminary results of a rando-
mized phase III trial comparing VNB 25 mg/m
2 on days
1,8 in combination with EPI 90 mg/m
2, with EPI as single
agent, showed a trend for higher response rate (50% vs
42%) and a significantly longer progression free survival
(10.1 vs 8.2 months) for the combination arm [17]. An
our previous clinical study with EPI/VNB combination as
first-line treatment showed a very high activity (70.6% of
response rate) and acceptable toxicity [18]; another our
experience testing the sequential administration of doce-
taxel for 4 cycles followed by 4 cycles of EPI/VNB as
first-line treatment for advanced disease, confirmed activ-
ity and tolerability of the regimen [19].
Incapsulating drugs in liposomes determine improve-
ment of solubility and stability of the drug, and prevent a
rapid degradation; moreover, specific toxicities are poten-
tially lowered and the efficacy increased, achieving a
higher therapeutic index [20]. Liposomal anthracyclines
exhibit efficacies comparable with those of conventional
anthracyclines, but with better safety profiles [21-24]. In
particular, data from retrospective analyses showed that
liposomal anthracyclines significant reduced the risk of
cardiotoxicity compared with conventional anthracy-
clines [25]. Phase III trials comparing pegylated liposomal
doxorubicin (PLD) with conventional anthracyclines
confirmed similar efficacy and lower toxicity than doxor-
ubicin [24,26], and results of several studies have shown
that PLD is effective in combination with other drugs
including taxanes, cyclophosphamide, gemcitabine [27].
As cardiotoxicity concerns, in a retrospective analysis a
low incidence of cardiac side effects were reported, even
at cumulative doses higher than 500 mg/m
2 [28]. The
combination of PLD with VNB was investigated in
anthracycline pretreated patients, with promising results
and manageable toxicity [29,30], but at the time we
design the present study no information about its first-
line use in comparison with a conventional anthracy-
cline-containing regimen were available, so we carried
out a prospective multicenter phase II randomized trial
of EPI/VNB versus PLD/VNB as first-line treatment for
advanced disease in patients not previously treated with
adjuvant anthracyclines.
Patients and Methods
Patient selection
Patients with histologically proven advanced breast cancer
not previously treated with adjuvant anthracyclines were
enrolled. Eligibility criteria included a life expectancy >
3 months, 18 to 75 years of age, WHO performance status
≤ 3, measurable/assessable disease, adequate bone marrow
(absolute neutrophil count ≥1,500, platelet count ≥
100,000, haemoglobin ≥ 11 g/dL), renal and liver function
(total bilirubin and creatinine <1.25 times the upper nor-
mal limits), and a normal cardiac function (left ventricular
ejection fraction LVEF ≥ 50% by echocardiography).
Patients were excluded from the study if they had active
cardiac diseases or significant arrhythmias, pre-existent
neuropathy, or had received prior chemotherapy treatment
for advanced disease, prior exposure to anthracyclines and
or vinorelbine, or if they had prior or concomitant malig-
nant disease, except appropriately treated basal cell carci-
noma of the skin or in situ carcinoma of the cervix.
Previous adjuvant chemotherapy with cyclophosphamide,
methotrexate, fluorouracil or similar regimens were
allowed, but an interval of two months should have
elapsed; hormonal adjuvant treatment and radiotherapy
must have been discontinued for at least 4 weeks before
study entry. The protocol was approved by the ethical
committees of each participant centers, and was carried
out according to Helsinki declaration and in accordance
with the International Conference on Harmonization
Good Clinical Practice guidelines.
Treatment
Patients were centrally assigned according to a compu-
ter generated random list to receive either (arm A) EPI
90 mg/m
2 i.v. on day 1 plus VNB 25 mg/m
2 i.v on days
1 and 5, with granulocyte colony-stimulating factor
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Page 2 of 8(G-CSF) subcutaneously on days 7-12 of each cycle, or
(arm B) PLD 40 mg/m
2 i.v. on day 1, plus VNB 30 mg/
m
2 on days 1 and 15. Cycles were repeated every
21 days in arm A, and every 28 days in arm B, for a
maximum of 8 cycles. Treatment was continued until
disease progression, severe toxicity, patient refusal.
Antiemetic treatment consisted of an antiserotonin
agent plus desamethasone in a 15 min infusion before
starting chemotherapy. Treatment was postponed by a
maximum of 2 weeks if the absolute neutrophil count
w a sl e s st h a n1 , 5 0 0 /μL or the platelet count was less
than 100,000/μL. A 25% drugs dose-reduction was
planned in case of grade 4 neutropenic fever, as well as
in case of grade 3 mucositis or neurotoxicity. G-CSF
was administered in arm B in case of grade 4 neutrope-
nic fever, and prophylactively in the subsequent cycles.
Treatment was discontinued in case of grade 4 neuro-
toxicity, mucositis, palmar plantar erythrodisesthesia
(PPE), treatment delay longer than 2 weeks, or in case
of cardiotoxicity, defined as LVEF decrease ≥ 20% from
baseline, or ≥10% but with a value below 50%, or any
symptoms of congestive heart failure or arrhythmias
even in absence of LVEF decrease. Hematologic assess-
ment was done on days 1 and 12 of every cycle in arm
A, and on days 1 and 14 in arm B, and whenever useful
at discretion of investigator.
Pretreatment and Follow Up Studies
Pretreatment investigations included complete blood
count and chemistry, chest x-ray, bone scan, CT abdo-
men, LVEF evaluation by echocardiography, and other
site-specific imaging as appropriate. Echocardiography
with LVEF evaluation had to be performed every 3
cycles, or whenever indicated at discretion of investiga-
tor; during the follow-up LVEF had to be determined
every 6 months.
Evaluation of Response and Toxicity
Tumor assessment was performed every 3 cycles, or
whenever appropriate, and responses were evaluated
according to RECIST criteria [31]. Progression free sur-
vival (PFS) was calculated starting from the date of ran-
domization to the date of disease progression, refusal or
death from any cause; overall survival (OS) was calcu-
lated starting from the date of randomization to the
date of death or last follow up evaluation. Toxicity was
assessed in each cycle according to National Cancer
Institute Common Toxicity Criteria (version 3.0).
Statistical Methods
The primary objective of the study was to evaluate the
overall response rate of the two regimens, secondarily
toxicity, progression free survival and overall survival.
The study was designed as a phase II trial with a ran-
dom assignement to a calibration arm A and to an
experimental arm B. The sample size for arm B was cal-
culated according to the design described by A’Hern
[32]. A sample size of 53 patients was considered suffi-
cient to give a 90% probability of rejecting a baseline
response rate of 35% with an exact 5% one-sided signifi-
cance test when the true response rate was 55%. The
drug regimen should have been considered for further
studies if at least 25 responses were observed. The cali-
bration arm had the same sample size. No formal com-
parison was planned. The objective response rate have
been reported with its 95% confidence interval. All
patients enrolled were considered in the intention-to-
treat population (ITT). This population have been eval-
uated for the efficacy analysis, which was performed
also on evaluable patients. Subjects who assumed at
least one dose of drug have been considered as denomi-
nator in the safety analysis.
The time to event analysis was performed according
the Kaplan-Meier method.
Results
Patients Characteristics
From March 2003 to November 2005, a total of 104
patients were enrolled from 4 oncologic centers of the
GOIM (Gruppo Oncologico Italia Meridionale), with
54 patients randomized to arm A (EPI/VNB) and 50
patients to arm B (PLD/VNB). All randomized patients
have been evaluated for activity and toxicity according
to ITT analysis. Patient characteristics are listed in
Table 1. None of the patients have received any
chemotherapy for advanced disease; 20 patients in arm
A and 21 patients in arm B had received adjuvant
chemotherapy, not including anthracyclines or vinka
alcaloids; 35 and 30 patients had received previous
adjuvant hormonal therapy, and 10 and 11 patients
had received endocrine treatment for advanced disease
in arm A and B, respectively. Median age was 63 and
61 years, 10 and 9 patients were premenopausal, 44
and 41 postmenopausal in arm A and B, respectively;
dominant site of disease was soft tissue in 3 (5.6%) and
9 (18.0%), bone in 11 (20.4%) and 9 (18.0%), viscera in
40 (74.0%) and 32 (64.0%) patients in arm A and B,
respectively. Hormonal receptors were positive (ER
and/or PgR) in 39 and 32 patients, negative in 13 and
15 patients, unknown in 2 and 3 patients in the two
arms, respectively. Her-2, retrospectively evaluated in
35 and 38 patients in arm A and B, was overexpressed
or amplified in 8 patients in each arm (14.8% and 16%,
respectively). The median number of chemotherapy
cycles administered was 6 in both arms (range, 1 to 8
in both arms).
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According to an intent to treat analysis, among 54
patients enrolled in arm A, there were 3 complete
response (5.6%) and 20 partial responses (37%), for an
overall response rate of 42.6% (95% CI, 29.3-55.9); disease
remained stable in 19 (35.2%), and progressive disease
was observed in 6 (11.1%) patients. Among 50 patients
enrolled in arm B, there were 8 complete responses
(16%) and 18 partial responses (36%), for an overall
response rate of 52% (95% CI, 38.2-65.8); disease
remained stable in 12 (24%), and disease progression
occurred in 9 (18%) patients (Table 2a). Six patients of
arm A and 3 patients of arm B were not evaluable for
response (4 refusal, 5 lost to follow up). Objective
response rates in 48 and 47 evaluable patients were
47.9% (95% CI, 33.9-61.9), and 55.3% (95% CI, 41.1-69.4)
in the arm A and B, respectively (Table 2b). Disease con-
trol (CRs + PRs + NC) was 87.5% in arm A and 80.8% in
arm B, respectively. Responses according to disease sites
in evaluable patients are reported in details on Table 2c,
and were as follows: arm A/B, soft tissue 66.6%/77.7%;
bone 33.3%/37.5%; viscera 50%/53.3%. No relevant differ-
ences in response rate was observed according to hormo-
nal receptor status, evidencing only a trend of higher
response in receptor negative tumors in both arms
(53.6% vs 45.7%, arm A; 60% and 53.1% arm B). No dif-
ferences in response rates have been observed by Her-2
status in both arms, but numbers are very small: arm A
Her-2 neg 54%, Her-2 pos 42.8%; arm B Her-2 neg 64%,
Her-2 pos 50%. Median time to response was 2 months
in both arms (range, 1 to 4 months). Median progression
free survival (Figure 1) was 10.7 months in arm A (95%
CI, 8.7-12.6), and 8.8 months in arm B (95% CI 7.1-10.5),
median overall survival (Figure 2) was 34.6 months in
arm A (95%CI, 19.5-49.8) and 24.8 months in arm B
(95% CI, 15.7-33.9).
Toxicity
Table 3 summarizes treatment-related main toxicities.
Overall, both treatment regimens were well tolerated.
The dose-limiting toxicity was, as expected, myelosup-
pression, with G3-4 neutropenia occurring in 18.5% and
22% of the patients of arm A and B, respectively, with
Table 1 Patient and tumor characteristics
Characteristics Arm A(EV) = 54 Arm B(PLD/V) = 50
No. % No. %
Age, years
Median 63 61
Range 27-70 35-69
Pre/Postmenopausal 10/44 9/41
Median ECOGPS (range) 1(0-3) 1(0-3)
*HR status
Positive 39 72.2 32 64.0
Negative 13 24.1 15 30.0
Unknown 2 3.7 3 6.0
HER-2 status
Positive
Negative
Unknown
Prior adjuvant chemotherapy** 20 37 21 42
Prior hormonal therapy
Adjuvant 35 64.8 30 60
Advanced 10 18.5 11 22
Disease free-interval (years)
< 1 10 11
1-5 30 28
>5 14 11
Dominant disease site
Viscera 40 74.0 32 64.0
Bone 11 20.4 9 18.0
Soft tissue 3 5.6 9 18.0
Number of disease site
1 23 42.6 23 46.0
2 23 42.6 18 36.0
≥ 3 8 42.6 9 18.0
*HR: hormonal receptor status.
**not including anthracyclines or vinka alkaloids.
EV: epirubicin/vinorelbine; PLD/V: pegylated liposomal doxorubicin/vinorelbine.
Table 2 Objective responses
2a. ITT on all enrolled patients
Arm A (EV) (54) Arm B (PLD/V) (50)
No. % No. %
CR 3 5.6 42.6% 8 16.0 52.0%
PR 20 37.0 42.6% 18 36.0 52.0%
NC 19 35.2 12 24.0
PD 6 11.1 9 18.0
2b. On evaluable patients
Arm A (EV) (54) Arm B (PLD/V) (47)
No. % No. %
CR 3 6.3 47.9% 8 17.0 55.3%
PR 20 41.6 47.9% 18 38.7 55.3%
NC 19 39.6 12 25.5
PD 6 12.5 9 19.2
2c. Overall response rates according to disease sites in evaluable
patients (%)
Arm A (EV) (48) Arm B (PLD/V) (47)
Soft tissue 66.6 77.7
Bone 33.3 37.5
Viscera 50. 53.3
Abbreviations: EV = epirubicin, vinorelbine; PLD/V = pegylated liposomal
doxorubicin/vinorelbine; ITT = intent to treat; CR = complete response; PR =
partial response; NC = no change; PD = progressive disease.
Vici et al. Journal of Experimental & Clinical Cancer Research 2011, 30:39
http://www.jeccr.com/content/30/1/39
Page 4 of 8grade 3-4 neutropenic fever observed in 3 (5.5%) patients
of arm A, and in 2 patients (4.0%) of arm B, in whom the
administration of G-CSF was required. A 25% EPI/VNB
dose-reduction was required in 7% of the patients,
whereas a 25% PLD/VNB dose-reduction was required in
2 (4%) patients. Grade 3 thrombocytopenia was encoun-
tered only in one patient in arm A. Grade 3 alopecia was
universal in arm A, whereas in arm B it was of grade 3
only in 50% of the patients. Mild (G1-2) nausea and
vomiting was encountered in 46.3%/44.0% of the patients
in the two arms, respectively. Grade 3 mucositis was
observed in 7.4% and 12% of the patients in arm A and B,
respectively. Reversible AST/ALT elevation was reported
in 2 patients in both arms, and mild and transient periph-
eral neurotoxicity was observed in 8 and 7 patients in
arm A and B, respectively, while it was of grade 3 in 1
patients in both arms. Grade 3 PPE or cutaneous toxicity
was observed in 3 (6%) patients of arm B, usually related
to treatment duration, and prompted to treatment dis-
continuation in 1 patient after 4 cycles. As cardiotoxicity
concerns, no cases of congestive heart failure have been
observed in the two arms. A transient and asymptomatic
≥ 20% LVEF decrease was encountered in 2 patients
(3.7%) in arm A, and this prompted to treatment discon-
tinuation after 5
th,a n d6 t hc y c l e ;c o m p l e t eL V E Fr e c o v -
ery was observed in two months. One case of transient
and reversible supraventricular tachyarrhythmia was
observed in arm A, during the last EPI infusion. The
median cumulative delivered EPI dose was 540 mg/m
2
(range, 90 to 720 mg/m
2); the median cumulative deliv-
ered PLD dose was 240 mg/m
2 (range, 40 to 320 mg/m
2).
No toxic deaths have been observed in the two arms.
Discussion
Currently, there is no “gold standard” therapy for
metastatic breast cancer, and treatment decisions must
be based on patient and tumor characteristics, and on
prior treatments. In the scenario of patients presenting
with advanced disease, still exists a subgroup who have
received only endocrine adjuvant therapy, or adjuvant
chemotherapy with CMF or CMF-like regimens and,
less frequently, there is a small cohort treated with
adjuvant taxanes-based or other anthracycline-free
regimens; moreover, there are also anthracycline pre-
treated patients with a very long free-interval, to be
considered still anthracycline sensitive. In all these
patient cohorts there is still the option to employ an
anthracycline-based regimen as first-line treatment for
advanced disease, mostly in hormonal receptor and/or
Her-2 negative tumors, where a “targeted” therapy is
not available.
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Figure 2 Overall Survival.
Table 3 Grade 3-4 NCI-CTC toxicities in 104 enrolled
patients
Arm A (EV = 54) Arm B (PLD/V = 50)
No. % No. %
Anemia 5 9.2 4 8
Neutropenia 10 18.5 11 22
Thrombocytopenia 1 1.8 - -
Febrile neutropenia 3 5.5 1 2.0
Hepatotoxicity 2 3.7 2 4.0
Mucositis 4 7.4 6 12
PPE/skin - - 3 6
Alopecia 54 100 25 50
Neurologic 1 1.8 1 2.0
Cardiac 2 3.7 - -
Abbreviations: NCI-CTC: National Cancer Institute Common Toxicity Criteria;
PPE: palmoplantar erithrodysthesia; EV: epirubicin/vinorelbine; PLD/V:
pegylated liposomal doxorubicin/vinorelbine
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both anthracycline-based chemotherapy regimens for
anthracycline-naïve advanced breast cancer patients,
even if lower than expected. Response rate, progression
free survival and overall survival observed in experimen-
tal arm B were comparable to those obtained in the
“calibration” EPI/VNB arm. As toxicity concerns, both
regimens were tolerable, with a higher incidence of feb-
rile neutropenia and G3 alopecia in arm A, and of grade
3 mucositis and cutaneous toxicity in arm B. As cardio-
toxicity concerns, the relatively low cumulative EPI dose
delivered (≤ 720 mg/m
2) did not allow to evidence sig-
nificant clinical cardiotoxicity in the arm A, with only
one case of arrhythmia, and a transient and asympto-
matic in LVEF decrease occurring in 2 patients (3.7%),
leading to a discontinuation of chemotherapy after 5
and 6 cycles, and with a complete recovery within two
months.
Analyzing literature data, the EPI/VNB regimen is
among the active, non-taxane, anthracycline-containing
combinations for breast cancer treatment, as confirmed
by definite results of the Scandinavian Breast Trial
Group [33], and other trials [18], but some instances of
clinical cardiac toxicity in terms of congestive heart fail-
ure or cardiomyopathy have been reported, with an inci-
dence of asymptomatic LVEF decrease ranging from
20%-30% [33,34], so there is an urgent need of introduce
new active and safer regimens for anthracycline-sensitive
breast cancer patients, and a recent metanalysis showed
a significant lower rate of both clinical and subclinical
heart failure in patients treated with liposomal anthracy-
clines, compared with conventional doxorubicin [35].
A number of phase II trials have recently evaluated
PLD in combination regimens with cyclophosphamide,
paclitaxel, docetaxel, gemcitabine, VNB, and with biolo-
gical agent such as trastuzumab or lapatinib, with
response rates ranging from 31% to 75%, frequently
occurring even in anthracycline pretreated patients [36],
and with negligible cardiotoxicity. In details, the PLD/
VNB combination was recently employed in two phase
II trials in heavily pretreated patients, yielding a
response rate of 36% and 39%, without any cardiac toxi-
city [37,38]. Two more recent reports with PLD/VNB
combination as first-line treatment in elderly patients
confirmed the good overall clinical response rate (36%
and 50%, respectively), and the high tolerability of the
regimen [39,40] suggesting, due to the safety profile of
the combination, the employment also in such “frail”
patient population.
An increasingly pertinent question in patients relap-
sing following adjuvant anthracyclines is whether there
is a role for anthracycline rechallenge in those with a
long free-interval. As a result of a high cardiac risk asso-
ciated with increasing cumulative anthracycline dose,
patients are often denied re-treatment in advanced set-
ting; the choice of a liposomal anthracycline allows the
possibility of re-treating an anthracycline-responsive dis-
ease without substantially increasing the cardiac risk
[36]; this option should not be excluded in fact, and
some evidences come from a recent report on first- line
chemotherapy selection in adjuvant anthracycline-
pretreated patients, where no differences have been
found between CMF-based and anthracycline-containing
regimens for their impact on the outcome of first-line
anthracycline treatment [41]. By this point of view, even
if our results are in anthracycline-naïve patients, the
activity and the low toxicity profile observed suggest
that the choice of a liposomal formulation can offer
the chance of a more tolerable regimen maintaing con-
ventional anthracyclines efficacy.
The results of the present trial indicated both EPI/VNB
and PLD/VNB as two reasonable choices as first-line
treatment for women with relapsed breast cancer not
previously treated with adjuvant anthracyclines; since
advanced breast cancer is still an incurable disease, the
goals of treatments are symptoms palliation with minimal
toxicity, and survival prolongation, possibly with regi-
mens active against cancer but also preserving patient’s
quality of life; in this context, our results are encouraging,
confirming the feasibility and efficacy of two anthracy-
cline-containing regimens and, particularly, of a regimen
devoided of cardiac toxicity and of other severe side
effects, such as PLD/VNB; the choice of this combination
could offer a better quality of life and, hopefully, a better
outcome to metastatic breast cancer patients.
Conclusions
Both anthracycline-based regimens evaluated as first-line
treatment in advanced breast cancer patients not pre-
viously treated with anthracyclines seems to be active
and well tolerated, and can be considered as a reason-
able choice in this subset of patients
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